Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix

Half of stage I-II SCNEC patients experienced disease failure within 3 years, and distant metastasis was an outstanding issue. EP regimen for at least 5 cycles improved long-term RFS after radical surgery. Additional radiation might be unnecessary, even in patients with high-risk factors.